Responses
Oral Presentations
SATURDAY, 15 JUNE 2019
Osteoarthritis: Research in motion
Late breaking abstract session
LB0005 MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: 24-WEEK RESULTS
Compose a Response to This Article
Other responses
No responses have been published for this article.